COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2
The paper gives data on the clinical efficiency and safety profile of long-term use of the infliximab (INF) biosimilar BCD-055 versus the reference drug Remicade® (REM) in a population of patients with active ankylosing spondylitis (AS).Subjects and methods. An international multicenter randomized d...
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2018-07-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2562 |
id |
doaj-f2ab7d59b1704636a39acc713ecb7947 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
A. M. Lila V. I. Mazurov E. V. Zonova O. B. Nesmeyanova T. V. Plaksina D. G. Krechikova O. V. Reshet’ko L. N. Denisov I. G. Gordeev T. G. Pokrovskaya O. V. Antipova T. V. Kropotina T. V. Povarova P. A. Shesternya E. N. Ushakova N. F. Soroka E. V. Kunder A. V. Eremeeva E. V. Chernyaeva R. A. Ivanov P. S. Pukhtinskaya |
spellingShingle |
A. M. Lila V. I. Mazurov E. V. Zonova O. B. Nesmeyanova T. V. Plaksina D. G. Krechikova O. V. Reshet’ko L. N. Denisov I. G. Gordeev T. G. Pokrovskaya O. V. Antipova T. V. Kropotina T. V. Povarova P. A. Shesternya E. N. Ushakova N. F. Soroka E. V. Kunder A. V. Eremeeva E. V. Chernyaeva R. A. Ivanov P. S. Pukhtinskaya COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2 Научно-практическая ревматология ankylosing spondylitis infliximab (remicade®) biosimilar bcd-055 |
author_facet |
A. M. Lila V. I. Mazurov E. V. Zonova O. B. Nesmeyanova T. V. Plaksina D. G. Krechikova O. V. Reshet’ko L. N. Denisov I. G. Gordeev T. G. Pokrovskaya O. V. Antipova T. V. Kropotina T. V. Povarova P. A. Shesternya E. N. Ushakova N. F. Soroka E. V. Kunder A. V. Eremeeva E. V. Chernyaeva R. A. Ivanov P. S. Pukhtinskaya |
author_sort |
A. M. Lila |
title |
COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2 |
title_short |
COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2 |
title_full |
COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2 |
title_fullStr |
COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2 |
title_full_unstemmed |
COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2 |
title_sort |
comparative evaluation of the long-term efficacy and safety of the infliximab biosimilar bcd-055 and reference infliximab in patients with ankylosing spondylitis: results of the international multicenter randomized double-blind phase iii clinical study asart-2 |
publisher |
IMA-PRESS LLC |
series |
Научно-практическая ревматология |
issn |
1995-4484 1995-4492 |
publishDate |
2018-07-01 |
description |
The paper gives data on the clinical efficiency and safety profile of long-term use of the infliximab (INF) biosimilar BCD-055 versus the reference drug Remicade® (REM) in a population of patients with active ankylosing spondylitis (AS).Subjects and methods. An international multicenter randomized double-blind Phase III clinical trial was conducted in 199 patients who were randomized into two groups in a 2:1 ratio and who received BCD-055 or REM at a dose of 5 mg/kg at 0, 2, and 6 weeks, then every 8 weeks. Efficiency assessment was made at 14, 30 and 54 weeks in patients who received at least one dose of INF [intent-to-treat (ITT)], as well as at 54 weeks in those who completed the study according to the Protocol (PP) (per protocol). The efficiency endpoints were the proportion of patients who had achieved ASAS20/ASAS40 responses; changes in BASDAI, BASMI, BASFI, MASES, and SF-36 scores. Immunogenicity was assessed by the proportion of patients in each group with identified binding and neutralizing antibodies (BAbs and NAbs) against INF. The safety analysis included the overall rate of adverse events (AEs), including those that met the respective criteria for serous AEs (SAEs), and grade 3–4 toxicity, as well as the number of cases of early termination of the study because of AEs and SAEs.Results and discussion. The ITT population included 199 patients and the PP one consisted of 161 people. The groups were not statistically different in the rate of and reasons for patient withdrawal from the study. A comparable number of patients achieved ASAS20/ASAS40 responses at 14, 30, 54 weeks (р ≥ 0.05). At 54 week, the proportion of patients who received BCD-055 and REM therapy and achieved an ASAS20 response was 67.42 and 52.24% in the ITT population (p = 0.053) and 80.91 and 68.63% in the PP population (p = 0.128). The BCD-055 and drug comparison groups achieved an ASAS40 response in 53.03 and 38.81% in the ITT population (p = 0.081) and in 63.64 and 50.98% in the PP one (p = 0.177). The proportion of persons with identified BAbs and NAbs was comparable: 21.26 and 3.15% in the BCD-055 group (p = 0.920) and 20.63 and 6.35% in the group REM (p = 0.443), respectively. It was found that the presence of NAbs did not affect the therapeutic response. Both groups did not differ in the detection rate and profile of AEs and SAEs or in the rate of patient withdrawal due to AEs. Most identified AEs were mild to moderate.Conclusion. The efficacy of the INF biosimilar BCD-055 used long in patients with AS did not significantly differ from that of the original drug REM; the safety profile of both drugs was comparable. |
topic |
ankylosing spondylitis infliximab (remicade®) biosimilar bcd-055 |
url |
https://rsp.mediar-press.net/rsp/article/view/2562 |
work_keys_str_mv |
AT amlila comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT vimazurov comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT evzonova comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT obnesmeyanova comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT tvplaksina comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT dgkrechikova comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT ovreshetko comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT lndenisov comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT iggordeev comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT tgpokrovskaya comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT ovantipova comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT tvkropotina comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT tvpovarova comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT pashesternya comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT enushakova comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT nfsoroka comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT evkunder comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT averemeeva comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT evchernyaeva comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT raivanov comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 AT pspukhtinskaya comparativeevaluationofthelongtermefficacyandsafetyoftheinfliximabbiosimilarbcd055andreferenceinfliximabinpatientswithankylosingspondylitisresultsoftheinternationalmulticenterrandomizeddoubleblindphaseiiiclinicalstudyasart2 |
_version_ |
1721235705450987520 |
spelling |
doaj-f2ab7d59b1704636a39acc713ecb79472021-08-02T09:05:51ZrusIMA-PRESS LLCНаучно-практическая ревматология1995-44841995-44922018-07-0156329330110.14412/1995-4484-2018-293-3012358COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2A. M. Lila0V. I. Mazurov1E. V. Zonova2O. B. Nesmeyanova3T. V. Plaksina4D. G. Krechikova5O. V. Reshet’ko6L. N. Denisov7I. G. Gordeev8T. G. Pokrovskaya9O. V. Antipova10T. V. Kropotina11T. V. Povarova12P. A. Shesternya13E. N. Ushakova14N. F. Soroka15E. V. Kunder16A. V. Eremeeva17E. V. Chernyaeva18R. A. Ivanov19P. S. Pukhtinskaya20V.A. Nasonova Research Institute of RheumatologyI.I. Mechnikov North-Western State Medical University, Ministry of Health of RussiaCity Polyclinic OneChelyabinsk Regional Clinical HospitalN.A. Semashko Nizhny Novgorod Regional Clinical HospitalDepartmental Hospital at the Smolensk Station, OAO «RZhD»Regional Clinical HospitalV.A. Nasonova Research Institute of RheumatologyO.M. Filatov City Clinical Hospital Fifteen, Moscow Healthcare DepartmentBelgorod State National Research UniversityIrkutsk City Clinical Hospital OneRegional Clinical HospitalRailway Clinical Hospital at the Saratov II Station OAO "RZhD"Professor V.F. VoinoYasenetsky Krasnoyarsk State Medical University, Ministry of Health of RussiaClinical Rheumatology Hospital Twenty-FiveCity Clinical Hospital Nine,First City Clinical HospitalZAO «BIOCAD»ZAO «BIOCAD»ZAO «BIOCAD»ZAO «BIOCAD»The paper gives data on the clinical efficiency and safety profile of long-term use of the infliximab (INF) biosimilar BCD-055 versus the reference drug Remicade® (REM) in a population of patients with active ankylosing spondylitis (AS).Subjects and methods. An international multicenter randomized double-blind Phase III clinical trial was conducted in 199 patients who were randomized into two groups in a 2:1 ratio and who received BCD-055 or REM at a dose of 5 mg/kg at 0, 2, and 6 weeks, then every 8 weeks. Efficiency assessment was made at 14, 30 and 54 weeks in patients who received at least one dose of INF [intent-to-treat (ITT)], as well as at 54 weeks in those who completed the study according to the Protocol (PP) (per protocol). The efficiency endpoints were the proportion of patients who had achieved ASAS20/ASAS40 responses; changes in BASDAI, BASMI, BASFI, MASES, and SF-36 scores. Immunogenicity was assessed by the proportion of patients in each group with identified binding and neutralizing antibodies (BAbs and NAbs) against INF. The safety analysis included the overall rate of adverse events (AEs), including those that met the respective criteria for serous AEs (SAEs), and grade 3–4 toxicity, as well as the number of cases of early termination of the study because of AEs and SAEs.Results and discussion. The ITT population included 199 patients and the PP one consisted of 161 people. The groups were not statistically different in the rate of and reasons for patient withdrawal from the study. A comparable number of patients achieved ASAS20/ASAS40 responses at 14, 30, 54 weeks (р ≥ 0.05). At 54 week, the proportion of patients who received BCD-055 and REM therapy and achieved an ASAS20 response was 67.42 and 52.24% in the ITT population (p = 0.053) and 80.91 and 68.63% in the PP population (p = 0.128). The BCD-055 and drug comparison groups achieved an ASAS40 response in 53.03 and 38.81% in the ITT population (p = 0.081) and in 63.64 and 50.98% in the PP one (p = 0.177). The proportion of persons with identified BAbs and NAbs was comparable: 21.26 and 3.15% in the BCD-055 group (p = 0.920) and 20.63 and 6.35% in the group REM (p = 0.443), respectively. It was found that the presence of NAbs did not affect the therapeutic response. Both groups did not differ in the detection rate and profile of AEs and SAEs or in the rate of patient withdrawal due to AEs. Most identified AEs were mild to moderate.Conclusion. The efficacy of the INF biosimilar BCD-055 used long in patients with AS did not significantly differ from that of the original drug REM; the safety profile of both drugs was comparable.https://rsp.mediar-press.net/rsp/article/view/2562ankylosing spondylitisinfliximab (remicade®)biosimilarbcd-055 |